Login to Your Account

Aragon's Series D Adds $50M To Advance ARN-509 in CRPC

By Catherine Shaffer
Staff Writer

Thursday, October 4, 2012

Aragon Pharmaceuticals Inc. parlayed its successful Phase II results in prostate cancer to a new financing round worth $50 million supported by existing investors and led by new investor venBio. The funds will support advancement of ARN-509 in castration-resistant prostate cancer (CRPC).

Aragon has raised a total of $88 million in 2012, having closed a $42 million Series C in March. (See BioWorld Today, March 6, 2012.)

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription